SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
of Report (Date
of Earliest event Reported): June 8, 2016
CHINA BIOLOGIC PRODUCTS, INC.
(Exact name of registrant as specified
in its charter)
|(State or other jurisdiction of
||(Commission File No.)
||(IRS Employer ID No.)|
|incorporation or organization)
|18th Floor, Jialong International Building |
|19 Chaoyang Park Road |
|Chaoyang District, Beijing 100125 |
|People’s Republic of China|
(Address of Principal Executive Offices)
Registrant's telephone number, including
(Former name or former address, if changed
since last report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
ITEM 7.01. REGULATION FD DISCLOSURE.
On June 8, 2016, China Biologic Products, Inc. (the “Company”)
completed an offering (the “Offering”) of 2,775,000 shares of its common stock by certain selling stockholders. The
Company did not sell any shares in the Offering and did not receive any proceeds from the sale of the common stock by the selling
stockholders in the Offering.
The Offering was made pursuant to an automatically effective
shelf registration statement filed with the Securities and Exchange Commission.
The information contained in this report shall not be deemed
to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”),
or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any
filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference
in such a filing.
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|Date: June 13, 2016
||CHINA BIOLOGIC PRODUCTS, INC.|
||/s/ David (Xiaoying) Gao
||David (Xiaoying) Gao
||Chief Executive Officer